Gene therapy for Cooley's anemia in a new mouse model

新小鼠模型中库利贫血的基因治疗

• 批准号: 7985265
• 负责人: STEFANO RIVELLA
• 金额: $ 5.4万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-10 至 2010-11-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7985265
• 关键词: Affect; Anemia; Cells; Chimera organism; Chimerism; Cooley' s anemia; Data; Dihydrofolate Reductase; Drug resistance; Elements; Erythroid Cells; Gene Expression; Genes; Genomics; Globin; Green Fluorescent Proteins; Hematopoietic; Hematopoietic stem cells; Hemoglobin; Hemoglobin concentration result; Hemoglobinopathies; Housekeeping; Human; Insulator Elements; Lentivirus Vector; Mus; O(6)-Methylguanine-DNA Methyltransferase; Phosphoglycerate Kinase; Production; Protein Isoforms; Reporter Genes; Residual state; Site; Stem cells; Subfamily lentivirinae; Surface; Thalassemia intermedia; Transgenic Mice; Transplantation; beta Globin; beta Thalassemia; cellular transduction; embryonic stem cell; gene therapy; mouse model; novel therapeutics; promoter; vector

DESCRIPTION (provided by applicant): Stem cell-based gene therapy offers a potential means to cure congenital severe hemoglobinopathies such as beta-thalassemia. For this reason we have constructed a lentiviral vector (TNS9) carrying the human beta-globin gene and demonstrated that with this vector we can obtain long-term correction of a mouse model affected by beta-thalassemia intermedia. Furthermore, this vector rescues a new lethal mouse model affected by beta-thalassemia major. However, in these mice the level of correction of the anemia and hemoglobin produced are not yet optimal. We believe that in order to unveil completely the potential of this gene therapy approach, we need to investigate, in this new mouse model of Cooley's anemia, (Aim 1) the correlation between the fraction of lentiviral transduced hematopoietic stem cells (HSC), the degree of BM chimerism and the corresponding level of anemia correction. For this purpose, we will generate a new lentiviral vector that combines expression of a reporter gene, such as the humanized red-shifted green fluorescent protein (hrGFP), in all the hematopoietic lineages and expression of the human beta-globin gene in erythroid cells (TNS9+GFP). To increase human beta-globin expression (Aim 2) we propose to generate new lentiviral vectors that could potentially increase hemoglobin production. We believe that we can raise hemoglobin production from TNS9 by extending the beta-globin promoter by 1 Kb and inserting a 1 Kb genomic region corresponding to the HS1 of the LCR. Another genomic element that could raise the level of hemoglobin production by diminishing the variability of expression at different genomic integration sites is the cHS4 insulator element. The production of new therapeutic vectors requires efficient strategies to compare and identify the best beta-globin encoding lentivirus. For this purpose we propose (Aim 3) to investigate the average level of expression of TNS9 versus the new lentiviral vectors (proposed in Aim 2) in BM chimeras. In addition, we propose (Aim 4) to generate transgenic mice from lentiviral transduced single copy ES cells to study the level of and variability in expression for each vector. Finally, insertion of selective drug resistance genes, dihydrofolate reductase (DHFR) versus methylguanine-DNA-methyltransferase (MGMT), will be evaluated (Aim 5) to enhance competitive repopulation of transduced stem cells expressing the human beta-globin gene.

描述（由申请人提供）： 基于干细胞的基因疗法提供了一种治愈先天性严重血红蛋白病（例如β-甲无血症）的潜在手段。因此，我们已经构建了携带人β-珠蛋白基因的慢病毒载体（TNS9），并证明，借助该载体，我们可以长期校正受β-丘脑中介质影响的小鼠模型。此外，该矢量挽救了一个受β-丘脑贫血专业影响的新的致命小鼠模型。但是，在这些小鼠中，产生的贫血和血红蛋白的矫正水平尚不最佳。我们认为，为了完全揭示这种基因治疗方法的潜力，我们需要在这种新的Cooley贫血的小鼠模型中研究（AIM 1）慢病毒转导的造血干细胞（HSC）的比例之间的相关性，BM Chimerism的程度和相应的贫血校正水平。为此，我们将在所有造血谱系和人类β-蛋白基因的表达中生成一个新的慢病毒载体，该植物病毒载体结合了报告基因的表达，例如人性化的红移绿色荧光蛋白（HRGFP）。为了增加人类β-珠蛋白的表达（AIM 2），我们建议产生可能增加血红蛋白产生的新慢病毒载体。我们认为，我们可以通过将β-球蛋白启动子扩展1 kb并插入与LCR HS1相对应的1 Kb基因组区域来提高TNS9的血红蛋白产生。 CHS4绝缘子元件是另一个可以通过降低不同基因组整合位点表达的变异性来提高血红蛋白产生水平的基因组元素。新的治疗媒介的生产需要有效的策略来比较和识别编码慢病毒的最佳β-珠蛋白。为此，我们建议（AIM 3）研究BM嵌合体中TNS9与新的慢病毒载体（AIM 2中提出）的平均表达水平。此外，我们建议（AIM 4）从慢病毒转导的单复制ES细胞中产生转基因小鼠，以研究每个载体的表达水平和变异性。最后，将评估选择性耐药性基因，二氢叶酸还原酶（DHFR）与甲基圭氨酸-DNA-DNA-甲基转移酶（MGMT）的插入（AIM 5），以增强表达人β-蛋白基因的变速器的竞争重现。

项目成果

Protective role of calreticulin in HFE hemochromatosis.

钙网蛋白在 HFE 血色素沉着症中的保护作用。

• DOI: 10.1016/j.freeradbiomed.2007.09.014
• 发表时间: 2008
• 期刊: Free radical biology & medicine
• 影响因子: 7.4
• 作者: Pinto,JorgeP;Ramos,Pedro;deAlmeida,SérgioF;Oliveira,Susana;Breda,Laura;Michalak,Marek;Porto,Graça;Rivella,Stefano;deSousa,Maria
• 通讯作者: deSousa,Maria

Regulation of iron absorption in hemoglobinopathies.

• DOI: 10.2174/156652408786241401
• 发表时间: 2008-11
• 期刊: Current molecular medicine
• 影响因子: 2.5
• 作者: Rechavi G;Rivella S
• 通讯作者: Rivella S

Exploring the role of hepcidin, an antimicrobial and iron regulatory peptide, in increased iron absorption in beta-thalassemia.

探索铁调素（一种抗菌和铁调节肽）在增加 β 地中海贫血铁吸收中的作用。

• DOI: 10.1196/annals.1345.069
• 发表时间: 2005
• 期刊: Annals of the New York Academy of Sciences.
• 作者: Breda,Laura;Gardenghi,Sara;Guy,Ella;Rachmilewitz,EliezerA;Weizer-Stern,Orly;Adamsky,Konstantin;Amariglio,Ninette;Rechavi,Gideon;Giardina,PatriciaJ;Grady,RobertW;Rivella,Stefano
• 通讯作者: Rivella,Stefano

Ineffective erythropoiesis and thalassemias.

• DOI: 10.1097/moh.0b013e32832990a4
• 发表时间: 2009-05
• 期刊: Current opinion in hematology
• 影响因子: 3.2
• 作者: Rivella S